DIAGNOS Inc., a Canadian pioneer in AI-powered healthcare screening solutions, has successfully raised CAD $2.01 million through a non-brokered private placement, strengthening its position in the early detection of critical health conditions.
The private placement, which closed on February 5, 2025, comprised 6,715,370 units priced at $0.30 per unit. Each unit consists of one common share and one common share warrant, with warrants exercisable at $0.40 per share over an 18-month period ending August 5, 2026.
Strategic Investment Details
As part of the transaction, DIAGNOS paid cash commissions of $39,246.72 and issued 130,821 finder's warrants to five qualified arms-length firms. These finder's warrants carry the same terms as the subscriber warrants, allowing holders to purchase shares at $0.40 until August 5, 2026.
The company has earmarked the net proceeds for several strategic initiatives, including:
- Product development of AI-based screening services
- Commercialization efforts for existing technologies
- Regulatory affairs management
- General administrative operations
Technology and Market Position
DIAGNOS's flagship technology, the FLAIRE Artificial Intelligence platform, enables rapid development and modification of healthcare screening applications. Their key product, CARA (Computer Assisted Retina Analysis), provides enhanced retinal imaging capabilities that facilitate clearer and more detailed analysis of eye examinations.
The CARA system stands out as a cost-effective solution for high-volume patient screening, offering healthcare providers improved efficiency in retinal image analysis. This technology represents a significant advancement in early detection capabilities for critical health issues.
Regulatory Compliance
All securities issued through this private placement are subject to a statutory hold period ending June 6, 2025. The completion of the placement remains contingent upon receiving all necessary approvals, including authorization from the TSX Venture Exchange, and the execution of formal documentation.
This funding round marks a significant milestone in DIAGNOS's growth trajectory, positioning the company to expand its AI-powered healthcare screening solutions and strengthen its market presence in the medical technology sector.
